8-K filing — 20/20 Biolabs, Inc. (AIDX)
Filed: 2026-08-17 AccNo: 0001213900-26-090746 Size: 327 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
20/20 Biolabs Q2 EPS $(0.26) Misses $(0.06) Estimate, Sales $730.571K Miss $891.000K Estimate
20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.06) by 333.33 percent. This is a 52.94 percent decrease over losses of $(0.17) per share from
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 12:40 PM
- Checked
- Aug 17, 2026, 12:40 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
20/20 BioLabs Mulls Merger, Acquisition, Licensing, JV, Commercial Collaborations Across East Asia Under Its Roll-Up Strategy
20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic
Read original at benzingaBioLabs Announces Standstill Agreement With Streeterville Capital Regarding Outstanding Series E Convertible Preferred Stock, Effective July 16
Under the terms of the Agreement, during the 120-day period beginning on the date of the Agreement, Streeterville has agreed not to convert any shares of Series E Preferred Stock into shares of the Company’s common
Read original at benzinga